Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
VVOS 
Vivos Therapeutics Inc (VVOS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: VVOS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -33.58% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 15.49M USD | Price to earnings Ratio - | 1Y Target Price 6.05 |
Price to earnings Ratio - | 1Y Target Price 6.05 | ||
Volume (30-day avg) 124943 | Beta 7.44 | 52 Weeks Range 1.91 - 6.28 | Updated Date 04/2/2025 |
52 Weeks Range 1.91 - 6.28 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.99 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-03-26 | When Before Market | Estimate -0.43 | Actual -0.28 |
Profitability
Profit Margin -86.19% | Operating Margin (TTM) -68.52% |
Management Effectiveness
Return on Assets (TTM) -60.87% | Return on Equity (TTM) -325.98% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 11940446 | Price to Sales(TTM) 1.06 |
Enterprise Value 11940446 | Price to Sales(TTM) 1.06 | ||
Enterprise Value to Revenue 0.82 | Enterprise Value to EBITDA -0.21 | Shares Outstanding 5889520 | Shares Floating 4567956 |
Shares Outstanding 5889520 | Shares Floating 4567956 | ||
Percent Insiders 8 | Percent Institutions 13.7 |
Analyst Ratings
Rating 5 | Target Price 6.3 | Buy - | Strong Buy 2 |
Buy - | Strong Buy 2 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Vivos Therapeutics Inc
Company Overview
History and Background
Vivos Therapeutics Inc. was founded in 2016. The company focuses on developing and commercializing innovative technologies and treatment modalities for treating mild-to-moderate obstructive sleep apnea (OSA) and snoring in adults. It has been developing the Vivos System.
Core Business Areas
- Medical Devices: Develops and commercializes the Vivos System, a non-surgical, non-pharmaceutical treatment for mild-to-moderate OSA and snoring.
- Education and Training: Provides training and education programs for dentists to effectively use the Vivos System.
Leadership and Structure
Kirk Huntsman serves as the CEO. The company has a standard corporate structure with a board of directors overseeing operations and various departments reporting to the executive team.
Top Products and Market Share
Key Offerings
- Vivos System: The Vivos System is a multi-disciplinary treatment approach that involves a series of custom oral appliances used in conjunction with a specific therapeutic protocol. Vivos does not have a large market share within the Sleep Apnea Market, with primary competitors as ResMed and Philips.
Market Dynamics
Industry Overview
The sleep apnea market is growing due to increased awareness, aging populations, and rising obesity rates. The market includes CPAP machines, oral appliances, and surgical procedures.
Positioning
Vivos Therapeutics positions itself as offering a non-surgical and non-pharmaceutical alternative to traditional OSA treatments like CPAP.
Total Addressable Market (TAM)
The global sleep apnea market is expected to reach billions of dollars. Vivos is positioned to capture a portion of this market by offering a non-invasive alternative and education to dental professionals.
Upturn SWOT Analysis
Strengths
- Non-surgical and non-pharmaceutical approach
- Proprietary technology
- Training and education programs for dentists
Weaknesses
- Limited clinical data compared to established treatments
- Relatively new to the market
- Requires dentist training and adoption
Opportunities
- Growing awareness of sleep apnea
- Increasing demand for non-invasive treatments
- Potential for expansion into new markets
Threats
- Competition from established players in the sleep apnea market (ResMed and Philips)
- Changes in reimbursement policies
- Potential for technological advancements by competitors
Competitors and Market Share
Key Competitors
- RMD
- PHG
- ALGN
Competitive Landscape
Vivos Therapeutics is a smaller player in the sleep apnea market. Its competitive advantage lies in its non-surgical approach. Its disadvantage is its limited market presence compared to established players.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Discuss Vivos Therapeuticsu00a0Inc's growth trends over the past years. Need official company data.
Future Projections: Provide projections for Vivos Therapeuticsu00a0Inc's future growth based on analyst estimates. Need data from analyst reports.
Recent Initiatives: Highlight recent strategic initiatives undertaken by Vivos Therapeuticsu00a0Inc. Need up-to-date company press releases.
Summary
Vivos Therapeutics is a small company developing a non-surgical approach to sleep apnea treatment. It's market share is small, and faces competition from established players with larger market share. Growth is dependent on dentist adoption and clinical data. Awareness and non-invasive approaches are opportunities.
Similar Companies
- RMD
- PHG
- ALGN
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Market Research Reports
- Analyst Reports
Disclaimers:
This analysis is based on available information and is not financial advice. Market conditions can change. Always consult with a qualified financial advisor before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Vivos Therapeutics Inc
Exchange NASDAQ | Headquaters Littleton, CO, United States | ||
IPO Launch date 2020-12-11 | Co-Founder, Chairman of the Board & CEO Mr. R. Kirk Huntsman | ||
Sector Healthcare | Industry Medical Devices | Full time employees 114 | Website https://www.vivos.com |
Full time employees 114 | Website https://www.vivos.com | ||
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.